Your browser is no longer supported. Please, upgrade your browser.
Settings
MYL Mylan N.V. daily Stock Chart
MYL [NASD]
Mylan N.V.
IndexS&P 500 P/E28.21 EPS (ttm)1.24 Insider Own6.12% Shs Outstand518.42M Perf Week-5.49%
Market Cap18.10B Forward P/E6.77 EPS next Y5.16 Insider Trans0.00% Shs Float484.06M Perf Month7.71%
Income652.90M PEG3.86 EPS next Q1.42 Inst Own86.90% Short Float2.03% Perf Quarter-9.09%
Sales11.59B P/S1.56 EPS this Y66.60% Inst Trans0.70% Short Ratio2.03 Perf Half Y-11.71%
Book/sh23.45 P/B1.49 EPS next Y9.77% ROA1.60% Target Price44.56 Perf Year-6.88%
Cash/sh0.99 P/C35.42 EPS next 5Y7.30% ROE4.30% 52W Range30.33 - 47.82 Perf YTD-17.47%
Dividend- P/FCF10.38 EPS past 5Y-0.10% ROI4.80% 52W High-26.98% Beta1.56
Dividend %- Quick Ratio0.80 Sales past 5Y11.90% Gross Margin40.60% 52W Low15.13% ATR1.37
Employees35000 Current Ratio1.30 Sales Q/Q-4.20% Oper. Margin9.10% RSI (14)51.71 Volatility3.40% 3.83%
OptionableYes Debt/Eq1.20 EPS Q/Q83.00% Profit Margin4.70% Rel Volume0.86 Prev Close35.14
ShortableYes LT Debt/Eq1.10 EarningsNov 05 AMC Payout0.00% Avg Volume4.83M Price34.92
Recom1.90 SMA204.84% SMA50-0.37% SMA200-8.43% Volume4,177,560 Change-0.63%
Nov-15-18Upgrade Argus Hold → Buy
Nov-06-18Upgrade BofA/Merrill Neutral → Buy
Oct-09-18Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-05-18Downgrade Mizuho Buy → Neutral
Aug-24-18Upgrade Evercore ISI In-line → Outperform
Aug-13-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Mar-15-18Reiterated Mizuho Buy $45 → $51
Mar-06-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-25-18Reiterated Susquehanna Positive $47 → $55
Jan-04-18Reiterated Citigroup Buy $48 → $58
Jan-03-18Initiated Leerink Partners Mkt Perform $44
Dec-12-17Initiated Guggenheim Buy $59
Nov-07-17Reiterated RBC Capital Mkts Sector Perform $32 → $37
Oct-04-17Reiterated BTIG Research Buy $42 → $45
Aug-22-17Downgrade Argus Buy → Hold
Aug-16-17Upgrade Citigroup Neutral → Buy
Aug-07-17Reiterated Morgan Stanley Equal-Weight $52 → $36
Jun-16-17Initiated Cantor Fitzgerald Neutral $41
May-22-17Upgrade Barclays Equal Weight → Overweight $47 → $50
Nov-16-18 04:20PM  David Einhorn's Top 4 Sells in 3rd Quarter GuruFocus.com
02:06PM  Momenta Moves On Motley Fool
Nov-14-18 12:18PM  Mylan May Make Generics but Its Charts are Starting to Look 'Name Brand' TheStreet.com
07:46AM  Jim Cramer Weighs In On Dropbox, Teva And More Benzinga
Nov-13-18 05:41PM  Edited Transcript of MYL earnings conference call or presentation 5-Nov-18 10:00pm GMT Thomson Reuters StreetEvents
Nov-09-18 04:10PM  Mylan and Theravance's COPD treatment gets FDA approval Reuters
03:25PM  Momenta (MNTA) Reports Narrower-Than-Expected Loss in Q3 Zacks
03:13PM  Theravance Biopharma and Mylan Receive FDA Approval for YUPELRI (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease PR Newswire
01:29PM  Mylan and Theravance Biopharma's COPD treatment gets FDA approval Reuters
Nov-08-18 12:45PM  Hedge Funds Think This Drugmaker is on the Verge of a Breakout Insider Monkey
08:32AM  Even Following the Latest Surge, Mylan Stock Has Plenty of Room to Grow InvestorPlace
Nov-07-18 12:30PM  Momenta Pharmaceuticals Inc (MNTA) Q3 2018 Earnings Conference Call Transcript Motley Fool
09:44AM  Company News For Nov 7, 2018 Zacks
07:52AM  Wall Street thought Mylan was headed for disasternow, analysts are raving MarketWatch
07:33AM  3 Big Stock Charts for Wednesday: Walt Disney, Skyworks Solutions and PG&E Corporation InvestorPlace
06:30AM  The Market Is Finally Embracing Long-Unloved Drug Stocks Barrons.com
Nov-06-18 11:49PM  US STOCKS-S&P 500 futures up as Democrats capture U.S. House Reuters +16.13%
05:23PM  Dow Gains 173 Points Because the Market Only Cares That Midterms Are Almost Over Barrons.com
04:35PM  US STOCKS-Wall St gains as investors look to U.S. elections Reuters
04:30PM  Why Mylan, Mosaic, and Martin Marietta Materials Jumped Today Motley Fool
03:56PM  5 Top Stock Trades for Wednesday: AMDs Teaming Up With Amazon? InvestorPlace
03:40PM  MarketPulse: Mylan Surges to Keep Health Care Stocks Well Above Flatline Investing.com
01:18PM  US STOCKS-Wall St inches higher ahead of U.S. election results Reuters
12:30PM  US STOCKS-Wall St edges higher in thin trading ahead of election results Reuters
11:58AM  Why Mylan N.V. Stock Is Soaring Today Motley Fool
11:15AM  Mylan (MYL) Earnings Beat, Revenues Miss Estimates in Q3 Zacks
10:51AM  US STOCKS-Wall St edges higher in thin trading ahead of election results Reuters
10:35AM  Mylan Shares Soar After Drugmaker's Earnings Top Forecasts TheStreet.com
09:30AM  Health Care Stocks Taking Center Stage Ahead Of US Midterms ACCESSWIRE
09:07AM  US STOCKS-Wall St to open slightly lower as U.S. elections kick off Reuters
07:43AM  Stocks making the biggest move premarket: CVS, Eli Lilly, Marriott, Mylan & more CNBC
06:56AM  [$$] Stocks to Watch: Booking Holdings, Mylan, Marriott, Altice USA, Avis The Wall Street Journal
06:33AM  Mylan N.V. Improves in the Third Quarter Thanks to International Sales Motley Fool
Nov-05-18 09:37PM  Mylan N.V. (MYL) Q3 2018 Earnings Conference Call Transcript Motley Fool
05:27PM  Drugmaker Mylan's profit beats on higher emerging markets sales Reuters
05:25PM  Mylan (MYL) Surpasses Q3 Earnings Estimates Zacks
04:53PM  Stocks making the biggest moves after hours: ELF Beauty, Booking Holdings, Avis, Marriott and more CNBC
04:50PM  Mylan Stock Is Soaring as Q3 Earnings Double, Top Expectations InvestorPlace
04:32PM  Mylan stock up after positive earnings report CNBC Videos
04:30PM  Drugmaker Mylan's third-quarter profit beats estimates Reuters
04:22PM  Mylan: 3Q Earnings Snapshot Associated Press
04:08PM  Mylan earnings double, stock gains despite revenue miss MarketWatch
04:06PM  Mylan's quarterly revenue falls 4 pct Reuters
04:01PM  Mylan Reports Third Quarter 2018 Results and Reaffirms 2018 Guidance PR Newswire
07:49AM  Mylan's Q3 Earnings Preview Benzinga
04:36AM  [$$] Mylan posts earnings beat despite weaker EpiPen sales Financial Times
Nov-02-18 11:41AM  Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO Zacks
Nov-01-18 12:50PM  Acorda (ACOR) Q3 Earnings Top Estimates, Ampyra Sales View Up Zacks
10:29AM  Glaxo (GSK) Beats on Q3 Earnings & Sales, Raises '18 View Zacks
Oct-31-18 04:18PM  Mylan (MYL) Q3 Earnings: Is a Disappointment in the Cards? Zacks
Oct-29-18 04:17PM  Knock Offs Loom For J&J's Blockbuster Why An Analyst Is Still Bullish Investor's Business Daily
10:31AM  Mylan (MYL) Q3 Earnings Preview: How Are Events Shaping Up? Zacks
09:00AM  Consolidated Research: 2018 Summary Expectations for Green Brick Partners, Alliqua BioMedical, Buckle, DaVita, CDK Global, and Mylan N.V Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-23-18 12:18PM  Everyone Loves Treasury Bonds When Stocks Are Slumping Barrons.com
Oct-19-18 12:51PM  Mylan Launches Hulio (Biosimilar Adalimumab) in Markets Across Europe PR Newswire
09:30AM  Mylan and Biocon Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab PR Newswire
08:28AM  The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut Benzinga
Oct-18-18 04:20PM  Mylan Adds to Women's Healthcare Portfolio With Launch of Generic Depo-Provera® Injection PR Newswire
08:30AM  Mylan to Release Third Quarter 2018 Financial Results on November 5, 2018 PR Newswire
Oct-15-18 03:38PM  Drug Companies To Disclose Pricing Information In Ads Benzinga
Oct-14-18 01:37PM  Bulls & Bears Of The Week: GE, Netflix, Nike, Twitter And More Benzinga
Oct-13-18 10:06PM  [$$] Rivals line up to take on worlds best-selling drug Financial Times
Oct-12-18 11:00PM  Here's Why Momenta Pharmaceuticals Tumbled 13.5% on Friday Motley Fool
03:29PM  AbbVie Permits US Sale of Sandoz's Humira Biosimilar GuruFocus.com
12:27PM  Mylan Prevails in Copaxone® 40mg/mL Litigation Against Teva in U.S. Appellate Court PR Newswire
10:32AM  U.S. appeals court upholds ruling that canceled Teva Copaxone patents Reuters
10:10AM  U.S. appeals court upholds ruling that canceled Teva Copaxone patents Reuters
09:23AM  AbbVie Settles With Novartis to Delay Humira Biosimilar in US Zacks
Oct-11-18 08:30AM  Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of YUPELRI (revefenacin) at the 2018 CHEST Annual Meeting PR Newswire -5.73%
Oct-09-18 02:59PM  Mylan downgraded as previous bullish thesis is now 'broken' MarketWatch
09:46AM  3 Headwinds Hindering Mylan Benzinga
08:00AM  Mapi Pharma Presents Phase II Extension Results of Glatiramer Acetate Depot (GA Depot) at ECTRIMS 2018 in Berlin GlobeNewswire
Oct-08-18 06:28PM  Generic-Drugs Stock Outlook: No Respite from Pricing Issues Zacks
08:30AM  Theravance Biopharma and Mylan to Present New Data from Studies of YUPELRI (revefenacin) at the 2018 CHEST Annual Meeting PR Newswire
Oct-04-18 03:20AM  Moody's: Biosimilars a growing challenge biotech drugs, with European market developing more quickly than the US Moody's
Oct-01-18 11:00PM  [$$] EpiPen dearth shows company and regulator failure Financial Times
Sep-28-18 07:22PM  [$$] Don Panoz Hopped From Pharmaceuticals to Wine, Resorts and Race Cars The Wall Street Journal
09:59AM  Forget Mylan, Invest in These 3 Generic/Drug Stocks Instead Zacks
07:50AM  Report: Developing Opportunities within Sunoco LP, Mylan N.V., Ares Management, Las Vegas Sands, PPL, and Nokia Future Expectations, Projections Moving into 2018 GlobeNewswire
Sep-26-18 12:32PM  Amgen's Neulasta Has a New Competitor in Europe GuruFocus.com
11:10AM  Theravance Up as CHMP Backs Trelegy Elipta Line Extension Zacks
Sep-24-18 04:47PM  Mylan's Biosimilar of Neulasta Gets Positive CHMP Opinion Zacks
07:00AM  Mylan Extends Commitment to Fight HIV/AIDS by Partnering with Atomo Diagnostics to Expand Access to HIV Self-Testing in Low- and Middle-Income Countries PR Newswire
Sep-21-18 09:30AM  Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim PR Newswire
08:57AM  Mylan Launches Authorized Generic of Ampyra® Tablets PR Newswire
Sep-20-18 03:46PM  FDA chief: Looking to regulate nicotine in cigarettes Fox Business Videos
07:00AM  Mylan and Fujifilm Kyowa Kirin Biologics Receive European Marketing Authorization for Hulio®, Biosimilar Adalimumab PR Newswire
05:02AM  EU approves fifth copy of AbbVie's $18 bln drug Humira Reuters
04:00AM  Mylan, Fujifilm win EU okay for copy of AbbVie's Humira Reuters
Sep-18-18 06:36PM  Theravance, Mylan Report Positive Data on COPD Drug Yupelri Zacks
Sep-17-18 08:30AM  Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of YUPELRI (revefenacin) in Oral Presentation at the European Respiratory Society International Congress PR Newswire
Sep-16-18 02:22PM  The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Sep-14-18 11:00AM  Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija Zacks
Sep-13-18 09:01AM  Mylan Adds to Cardiovascular Portfolio With Launch of First Generic of Brevibloc® Injection in Single-Dose Bags PR Newswire
Sep-11-18 04:22PM  Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of YUPELRI (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018 PR Newswire
09:16AM  Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down Zacks
07:46AM  Dodd-Frank is a disaster and won't protect us from the ne... CNBC Videos
Sep-10-18 09:14AM  New Strong Sell Stocks for September 10th Zacks
Sep-07-18 09:30AM  Why Is Mylan (MYL) Up 6.3% Since Last Earnings Report? Zacks
Sep-06-18 02:12PM  These Hospital Systems Are Aiming To Undercut Biotechs, Drugmakers Investor's Business Daily
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; anti-retroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology, oncology, and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and Dymista, which is used for the treatment of seasonal allergic rhinitis. Further, it markets OTC products, including Cold-EEZE, Midnite, and Vivarin. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, group purchasing organizations, and government entities; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. Mylan N.V. has collaboration and license agreements with Pfizer Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., and Biocon Ltd. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CAMERON WENDYDirectorJun 29Option Exercise0.004,028076,735Jul 03 04:35 PM
Campbell PaulSee RemarksMar 06Sale44.017,030309,39017,522Mar 06 08:32 PM
COURY ROBERT JDirectorMar 06Sale43.4150,0002,170,685271,115Mar 06 08:10 PM
Campbell PaulSee RemarksMar 04Option Exercise0.001,081018,052Mar 06 08:32 PM
Mauro AnthonyChief Commercial OfficerMar 04Option Exercise0.0015,9360153,443Mar 06 08:29 PM
Malik RajivPresidentMar 04Option Exercise0.0040,7960549,146Mar 06 08:27 PM
BRESCH HEATHER MChief Executive OfficerMar 04Option Exercise0.0066,2920564,408Mar 06 08:26 PM
Campbell PaulSee RemarksMar 03Option Exercise0.002200220Mar 06 08:32 PM
Campbell PaulSee RemarksMar 03Option Exercise0.00831017,054Mar 06 08:32 PM
Parks Kenneth ScottChief Financial OfficerMar 03Option Exercise0.003,98506,800Mar 06 08:30 PM
Mauro AnthonyChief Commercial OfficerMar 03Option Exercise0.005,5340140,712Mar 06 08:29 PM
Malik RajivPresidentMar 03Option Exercise0.0012,3950516,146Mar 06 08:27 PM
Gallagher Daniel Martin JrChief Legal OfficerMar 03Option Exercise0.008,21808,218Mar 06 08:26 PM
BRESCH HEATHER MChief Executive OfficerMar 03Option Exercise0.0020,1420510,917Mar 06 08:26 PM
Vollebregt Sjoerd SDirectorMar 03Option Exercise0.004,23004,230Mar 06 08:25 PM
VANDERVEEN RANDALL LDirectorMar 03Option Exercise0.003,653043,342Mar 06 08:24 PM
PARRISH MARK WDirectorMar 03Option Exercise0.003,653038,920Mar 06 08:22 PM
HIGGINS MELINA EDirectorMar 03Option Exercise0.003,65309,092Mar 06 08:22 PM
DIMICK NEIL FDirectorMar 03Option Exercise0.003,653046,142Mar 06 08:18 PM
Lyons Dillon JoEllenDirectorMar 03Option Exercise0.003,653011,164Mar 06 08:13 PM
Cindrich Robert JDirectorMar 03Option Exercise0.003,653020,604Mar 06 08:09 PM
CAMERON WENDYDirectorMar 03Option Exercise0.003,653074,232Mar 06 08:08 PM
Mauro AnthonyChief Commercial OfficerMar 02Option Exercise22.664,757107,794147,435Mar 06 08:29 PM
Mauro AnthonyChief Commercial OfficerMar 02Sale40.3512,257494,570135,178Mar 06 08:29 PM
Malik RajivPresidentMar 02Sale40.9150,0002,045,695503,751Mar 06 08:27 PM
COURY ROBERT JDirectorMar 02Sale40.10150,0006,014,625321,115Mar 06 08:10 PM
Mauro AnthonyChief Commercial OfficerFeb 17Option Exercise0.003,5300144,183Feb 21 06:38 PM
Parks Kenneth ScottChief Financial OfficerFeb 17Option Exercise0.002,15003,518Feb 21 06:37 PM
Malik RajivPresidentFeb 17Option Exercise0.006,4840556,339Feb 21 06:37 PM
BRESCH HEATHER MChief Executive OfficerFeb 17Option Exercise0.0011,2390495,778Feb 21 06:38 PM
Campbell PaulSee RemarksFeb 17Option Exercise0.00540016,488Feb 21 06:36 PM
BRESCH HEATHER MChief Executive OfficerJan 09Sale45.0030,9331,391,985484,539Jan 10 09:00 PM
BRESCH HEATHER MChief Executive OfficerJan 08Sale45.0044,0671,983,015515,472Jan 10 09:00 PM